Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardunizumab plus TP induction followed by cisplatin chemoradiotherapy for locally advanced cervical cancer with bulky/fused lymph nodes
ChiCTR2400083624Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- Apr 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoint: Tumor shrinkage rate after concurrent chemoradiotherapy. Started Apr 2024; status: recruiting.
02
Drugs
cadonilimabpaclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400083624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083624.